Pacira Biosciences, Stock Today

PCRX Stock  USD 16.00  0.52  3.15%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 1

 
High
 
Low
Very Small
Pacira BioSciences, is trading at 16.00 as of the 7th of October 2024; that is 3.15% down since the beginning of the trading day. The stock's open price was 16.52. Pacira BioSciences, has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Note, on June 23, 2021, Representative Tom Malinowski of US Congress acquired under $15k worth of Pacira BioSciences,'s common stock.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
3rd of February 2011
Category
Healthcare
Classification
Health Care
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida. The company has 46.13 M outstanding shares of which 5.75 M shares are at this time shorted by private and institutional investors with about 4.66 trading days to cover. More on Pacira BioSciences,

Moving together with Pacira Stock

  0.81EVO Evotec SE ADRPairCorr

Moving against Pacira Stock

  0.7GLUE Monte Rosa TherapeuticsPairCorr
  0.69JNJ Johnson Johnson Sell-off TrendPairCorr
  0.65BMY Bristol Myers Squibb Aggressive PushPairCorr
  0.64ZTS Zoetis IncPairCorr
  0.63FHTX Foghorn TherapeuticsPairCorr
  0.62NRIX Nurix Therapeutics Earnings Call This WeekPairCorr

Pacira Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEO DirectorFrank Lee
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, SP Small-Cap 600, NASDAQ Health Care, NASDAQ Composite, NASDAQ Composite Total, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.340.4287
Significantly Down
Very volatile
Total Current Liabilities123.5 M97.4 M
Significantly Up
Slightly volatile
Non Current Liabilities Total637.2 M606.9 M
Sufficiently Up
Slightly volatile
Total Assets1.7 B1.6 B
Sufficiently Up
Slightly volatile
Total Current Assets331.8 M510 M
Way Down
Slightly volatile
Debt Levels
Pacira BioSciences, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Pacira BioSciences,'s financial leverage. It provides some insight into what part of Pacira BioSciences,'s total assets is financed by creditors.
Liquidity
Pacira BioSciences, currently holds 586.04 M in liabilities with Debt to Equity (D/E) ratio of 1.1, which is about average as compared to similar companies. Pacira BioSciences, has a current ratio of 3.87, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Pacira BioSciences,'s use of debt, we should always consider it together with its cash and equity.

Total Cash From Operating Activities

162.38 Million
Pacira BioSciences, (PCRX) is traded on NASDAQ Exchange in USA. It is located in 5401 West Kennedy Boulevard, Tampa, FL, United States, 33609 and employs 711 people. Pacira BioSciences, is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 761.79 M. Pacira BioSciences, conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 46.13 M outstanding shares of which 5.75 M shares are at this time shorted by private and institutional investors with about 4.66 trading days to cover. Pacira BioSciences, currently holds about 316.39 M in cash with 154.65 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.9.
Check Pacira BioSciences, Probability Of Bankruptcy
Ownership Allocation
The majority of Pacira BioSciences, outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Pacira BioSciences, to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Pacira BioSciences,. Please pay attention to any change in the institutional holdings of Pacira BioSciences, as this could imply that something significant has changed or is about to change at the company. Please note that on June 23, 2021, Representative Tom Malinowski of US Congress acquired under $15k worth of Pacira BioSciences,'s common stock.
Check Pacira Ownership Details

Pacira Stock Institutional Holders

InstituionRecorded OnShares
Rice Hall James & Associates, Llc2024-06-30
998.6 K
Marshall Wace Asset Management Ltd2024-06-30
971.1 K
Baillie Gifford & Co Limited.2024-06-30
806.1 K
Rock Springs Capital Management Lp2024-06-30
785 K
Nuveen Asset Management, Llc2024-06-30
711.2 K
Hhg Plc2024-06-30
698.4 K
Schroder Investment Management Group2024-06-30
616.8 K
Abrdn Plc2024-06-30
609.4 K
Jpmorgan Chase & Co2024-06-30
600.6 K
Blackrock Inc2024-06-30
M
Vanguard Group Inc2024-06-30
5.1 M
View Pacira BioSciences, Diagnostics

Pacira BioSciences, Historical Income Statement

At this time, Pacira BioSciences,'s Income Tax Expense is fairly stable compared to the past year. Net Income From Continuing Ops is likely to rise to about 7.3 M in 2024, whereas Interest Expense is likely to drop slightly above 16.1 M in 2024. View More Fundamentals

Pacira Stock Against Markets

Pacira BioSciences, Corporate Management

Richard KahrVice ResourcesProfile
Daryl GauglerChief OfficerProfile
Charles LaranjeiraChief Technical OfficerProfile
Christopher YoungChief OfficerProfile
DO EllisChief OfficerProfile
III CPAChief OfficerProfile
Max ReinhardtPres WorldProfile

Additional Tools for Pacira Stock Analysis

When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.